Yahoo Finance20d
Oragenics, Inc. Submits Investigator’s Brochure for Phase II Clinical Trial of ONP-002 in Mild Traumatic Brain Injury (mTBI)
Despite the high incidence of concussions, no FDA-approved drug therapies currently exist, leaving a significant unmet medical need. “The submission of our Investigator’s Brochure application ...
Australian Football League16y
Management of concussion
the AFL Research Board and the AFL Medical Officers Association have produced a position statement and policy covering the management of concussion in Australian football at all levels. The attached ...
Nasdaq20d
Oragenics, Inc. Submits Investigator's Brochure for Phase II Clinical Trial of ONP-002 in Australia for Mild Traumatic Brain Injury
Despite the high incidence of concussions, no FDA-approved drug therapies currently exist, leaving a significant unmet medical need. “The submission of our Investigator’s Brochure application ...
Oragenics, Inc. Submits Investigator’s Brochure for Phase II Clinical Trial of ONP-002 in Mild Traumatic Brain Injury (mTBI)
Oragenics, Inc. (NYSE American: OGEN), a biotechnology company advancing innovative treatments for concussion and brain-related health conditions, today announced the submission of its Investigator’s ...